Clinical progression in Parkinson disease and the neurobiology of axons

Cited by (1,001)

Items 101–200 of 1,001

1. Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome
   Brian T. Bicknell, Ann D. Liebert, Thomas Julius Borody, GK Herkes, Craig Steven McLachlan, Hosen Kiat · 2023 · International Journal of Molecular Sciences
2. The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses
   Asad Jan, Nádia Pereira Gonçalves, Christian Bjerggaard Vægter, Poul Henning Jensen, Nelson Ferreira · 2021 · International Journal of Molecular Sciences
3. Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?
   Yvette C. Wong, Kelvin C. Luk, Kerry Purtell, Samuel Burke, A. Jon Stoessl, Louis‐Éric Trudeau, Zhenyu Yue, Dimitri Krainc, Wolfgang Hermann Oertel, Jose Angel Obeso et al. · 2019 · Movement Disorders
4. Primum Non Nocere: An Evolutionary Analysis of Whether Antidepressants Do More Harm than Good
   Andrews, Paul W., Thomson, J. Anderson, Amstadter, Ananda, Neale, Michael C. · 2012 · Frontiers in Psychology
5. Neurodegeneration and the ordered assembly of α-synuclein
   Maria Grazia Spillantini, Michel Goedert · 2017 · Cell and Tissue Research
6. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson’s disease model
   Tomoyuki Taguchi, Masashi Ikuno, Mari Hondo, Laxmi Kumar Parajuli, Katsutoshi Taguchi, Jun Ueda, Masanori Sawamura, Shinya Okuda, Etsuro Nakanishi, Junko Hara et al. · 2019 · Brain
7. α-Synuclein in Parkinson’s disease: causal or bystander?
   Peter Franz Riederer, Daniela Berg, Nicolas Casadei, Fubo Cheng, Joseph Claßen, Christian Dresel, Wolfgang H. Jost, Rejko Krüger, Thomas H. Müller, Heinz Reichmann et al. · 2019 · Journal of Neural Transmission
8. The neural stem cell secretome and its role in brain repair
   Cory M. Willis, Alexandra M. Nicaise, Luca Peruzzotti‐Jametti, Stefano Pluchino · 2019 · Brain Research
9. Neuropathogenesis-on-chips for neurodegenerative diseases
   Sarnai Amartumur, Huong Mai Nguyen, Thuy Huynh, Testaverde S. Kim, Ran‐Sook Woo, Eungseok Oh, Kyeong Kyu Kim, Luke P. Lee, Chaejeong Heo · 2024 · Nature Communications
10. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
    Atsushi Fujita, Hiroo Yamaguchi, Ryo Yamasaki, Yiwen Cui, Yuta Matsuoka, Ken‐ichi Yamada, Jun‐ichi Kira · 2018 · Journal of Neuroinflammation
11. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease
    E. Maruthi Prasad, Shih‐Ya Hung · 2020 · Antioxidants
12. Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons
    Lauren Y. Shields, H Kim, Lena Zhu, Dominic Haddad, Amandine Berthet, Divya Pathak, Mable Lam, Ravikumar Ponnusamy, L. Grisell Diaz‐Ramirez, T M Gill et al. · 2015 · Cell Death and Disease
13. Genetics of Parkinson's disease
    Ajith Cherian, Kalikavil Puthanveedu Divya · 2020 · Acta Neurologica Belgica
14. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice
    Karikari, Akua A., McFleder, Rhonda L., Ribechini, Eliana, Blum, Robert, Bruttel, Valentin, Knorr, Susanne, Gehmeyr, Mona, Volkmann, Jens, Brotchie, Jonathan M., Ahsan, Fadhil et al. · 2022 · Brain, Behavior, and Immunity
15. Synuclein deposition and non-motor symptoms in Parkinson disease
    K. A. Jellinger · 2011 · Journal of the Neurological Sciences
16. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
    A. Van der Perren, J. Toelen, C. Casteels, F. Macchi, A. Van Rompuy, S. Sarre, N. Casadei, S. Nuber, U. Himmelreich, M. I. Osorio Garcia et al. · 2015 · Neurobiology of Aging
17. Plants-derived neuroprotective agents: cutting the cycle of cell death through multiple mechanisms
    Elufioye, Taiwo Olayemi, Berida, Tomayo Ireti, Habtemariam, Solomon · 2017 · Evidence-based Complementary and Alternative Medicine
18. AAV transduction of dopamine neurons with constitutively active rheb protects from neurodegeneration and mediates axon regrowth
    Kim, Sang Ryong, Kareva, Tatyana, Yarygina, Olga, Kholodilov, Nikolai, Burke, Robert E · 2012 · Molecular Therapy
19. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker
    Rahul Gaurav, Lydia Yahia‐Cherif, Nadya Pyatigorskaya, Graziella Mangone, Emma Biondetti, Romain Valabrègue, Claire Ewenczyk, R. Matthew Hutchison, Jesse M. Cedarbaum, Jean‐Christophe Corvol et al. · 2021 · Movement Disorders
20. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model
    Thomas Musacchio, Maike Rebenstorff, Felix Fluri, Jonathan M. Brotchie, Jens Volkmann, James B. Koprich, Chi Wang Ip · 2017 · Annals of Neurology
21. Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease
    Lijuan Hou, Wei Chen, Xiaoli Liu, Decai Qiao, Fu-Ming Zhou · 2017 · Frontiers in Aging Neuroscience
22. The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models
    Per Borghammer · 2023 · Journal of Neural Transmission
23. The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration
    Danielle E. Mor, Malcolm J. Daniels, Harry Ischiropoulos · 2019 · Movement Disorders
24. Axonal degeneration in tauopathies: disease relevance and underlying mechanisms
    Kneynsberg, Andrew, Combs, Benjamin, Christensen, Kyle, Morfini, Gerardo, Kanaan, Nicholas M. · 2017 · Frontiers in Neuroscience
25. Nigrostriatal dopamine transporter availability in early Parkinson's disease
    Patrik Fazio, Per Svenningsson, Zsolt Cselényi, Christer Halldin, Lars Farde, Andrea Varrone · 2018 · Movement Disorders
26. Molecular Imaging of the Dopamine Transporter
    Giovanni Palermo, Roberto Ceravolo · 2019 · Cells
27. Diffusion Tensor Imaging in Parkinson's Disease and Parkinsonian Syndrome: A Systematic Review
    Yu Zhang, Marc A. Burock · 2020 · Frontiers in Neurology
28. Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons
    Steinkellner, Thomas, Zell, Vivien, Farino, Zachary J., Sonders, Mark S., Villeneuve, Michael, Freyberg, Robin J., Przedborski, Serge, Lu, Wei, Freyberg, Zachary, Hnasko, Thomas S. · 2018 · Journal of Clinical Investigation
29. Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
    Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson · 2020 · Frontiers in Immunology
30. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease
    Christopher E. J. Doppler, Martin Byskov Kinnerup, Corinna Brune, Ezequiel Farrher, Matthew J. Betts, Tatyana Dmitrievna Fedorova, Jeppe L. Schaldemose, Karoline Knudsen, Rola Ismail, Aline Seger et al. · 2021 · Brain
31. Cerebral magnetic resonance elastography in supranuclear palsy and idiopathic Parkinson's disease
    Axel Lipp, Radmila Trbojevic, Friedemann Paul, Andreas Fehlner, Sebastian Hirsch, Michael Scheel, Cornelia Noack, Jürgen Braun, Ingolf Sack · 2013 · NeuroImage Clinical
32. Paraquat and Parkinson’s disease: a systematic review and meta-analysis of observational studies
    Carolina Vaccari, Regina El Dib, Huda A. Gomaa, Luciane Cruz Lopes, João Lauro Viana de Camargo · 2019 · Journal of Toxicology and Environmental Health Part B
33. Therapy of Parkinson's Disease Subtypes
    Connie Marras, К. Ray Chaudhuri, Nataliya Titova, Tiago Mestre · 2020 · Neurotherapeutics
34. Neuroglial transmitophagy and Parkinson's disease
    Ingrid Moráles, Alberto Sánchez, Ricardo Puertas‐Avendaño, Clara Rodriguez‐Sabate, Adrian Perez‐Barreto, Manuel Rodrı́guez · 2020 · Glia
35. Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease
    Julia Benkert, Simon Heß, Shoumik Roy, Dayne A. Beccano-Kelly, Nicole Burkert, Johanna Duda, Carsten Simons, Komal Patil, Aisylu Gaifullina, Nadja Mannal et al. · 2019 · Nature Communications
36. Old and new challenges in Parkinson's disease therapeutics
    Ana O. Pires, Fábio Gabriel Teixeira, Bárbara Mendes-Pinheiro, Sofia Cravino Serra, Nuno Sousa, António José Salgado · 2017 · Progress in Neurobiology
37. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism
    Päivi Lindholm, Märt Saarma · 2021 · Molecular Psychiatry
38. Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease
    Jensen, Melanie P., Jacobs, Benjamin Meir, Dobson, Ruth, Bandres‐Ciga, Sara, Blauwendraat, Cornelis, Schrag, Anette, Noyce, Alastair J., The International Parkinson's Disease Genomics Consortium (IPDGC) · 2021 · Annals of Neurology
39. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease
    Ulrika Nordström, Geneviève Beauvais, Anamitra Ghosh, P. S. Baby Chakrapani, Martin Lundblad, Julia Fuchs, Rajiv L. Joshi, Jack W. Lipton, Andrew Roholt, Satish Medicetty et al. · 2014 · Neurobiology of Disease
40. Morphological and Behavioral Impact of AAV2/5-Mediated Overexpression of Human Wildtype Alpha-Synuclein in the Rat Nigrostriatal System
    Sara E. Gombash, Fredric P. Manfredsson, Christopher J. Kemp, Nathan C. Kuhn, Sheila M. Fleming, Ann E. Egan, Laura M. Grant, Michelle R. Ciucci, Jeffrey P. MacKeigan, Caryl E. Sortwell · 2013 · PLoS ONE
41. Brainstem: Neglected Locus in Neurodegenerative Diseases
    Lea T. Grinberg, Udo Rueb, Helmut Heinsen · 2011 · Frontiers in Neurology
42. The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress
    Stephanie E. Oh, Hye-Jin Park, Liqiang He, Catherine Skibiel, Eunsung Junn, M. Maral Mouradian · 2018 · Redox Biology
43. Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
    Ilaria Cova, Alberto Priori · 2018 · Journal of Neural Transmission
44. T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease
    Yoshikuni Tabata, Yoichi Imaizumi, Michiko Sugawara, Tomoko Andoh-Noda, Satoe Banno, MuhChyi Chai, Takefumi Sone, Kazuto Yamazaki, Masashi Ito, Kappei Tsukahara et al. · 2018 · Stem Cell Reports
45. Speech and language biomarkers for Parkinson’s disease prediction, early diagnosis and progression
    Fangyuan Cao, Adam P. Vogel, Puya Gharahkhani, Miguel E. Rentería · 2025 · npj Parkinson s Disease
46. Parkinson’s Disease Detection Using Hybrid LSTM-GRU Deep Learning Model
    Amjad Ur Rehman, Tanzila Saba, Muhammad Mujahid, Faten Sae Alamri, Narmine ElHakim · 2023 · Electronics
47. A blood-based marker of mitochondrial DNA damage in Parkinson’s disease
    Rui Qi, Esther M. Sammler, Claudia P. González-Hunt, Ivana Barraza, Nicholas Pena, Jeremy P. Rouanet, Yahaira Naaldijk, Steven D. Goodson, Marie Fuzzati, Fabio Blandini et al. · 2023 · Science Translational Medicine
48. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
    Gennaro Pagano, Frank Boess, Kirsten I. Taylor, Benedicte Ricci, Brit Mollenhauer, Werner H Poewe, Anne Boulay, Judith Anzures‐Cabrera, Annamarie Vogt, Maddalena Marchesi et al. · 2021 · Frontiers in Neurology
49. Neurotrophic Factors in Parkinson’s Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain
    Olesja M. Bondarenko, Märt Saarma · 2021 · Frontiers in Cellular Neuroscience
50. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes
    Karoline Knudsen, Tatyana Dmitrievna Fedorova, Jacob Horsager, Katrine B. Andersen, Casper Skjærbæk, Daniela Berg, Eva Schaeffer, David James Brooks, Nicola Pavese, Nathalie Van Den Berge et al. · 2021 · Journal of Parkinson s Disease
51. Gut-first Parkinson’s disease is encoded by gut dysbiome
    Mario Muñoz, Emanuel Candeias, Inês Melo-Marques, A. Raquel Esteves, Ana Maranha, João Duarte Magalhães, Diogo Reis Carneiro, Mariana Sant’Anna, A. Raquel Pereira-Santos, António E. Abreu et al. · 2024 · Molecular Neurodegeneration
52. Overexpression of TFEB Drives a Pleiotropic Neurotrophic Effect and Prevents Parkinson’s Disease-Related Neurodegeneration
    Albert Torra, Annabelle Parent, Thaïs Cuadros, Beatriz Rodríguez-Galván, Esther Ruiz‐Bronchal, Andrea Ballabio, Analı́a A Bortolozzi, Miquel Vila, Jordi Bové · 2018 · Molecular Therapy
53. Progressive Decline in Gray and White Matter Integrity in de novo Parkinson’s Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data
    Kirsten I. Taylor, Fabio Sambataro, Frank Boess, Alessandro Bertolino, Juergen Dukart · 2018 · Frontiers in Aging Neuroscience
54. Enhanced Efficacy of the CDNF/MANF Family by Combined Intranigral Overexpression in the 6-OHDA Rat Model of Parkinson's Disease
    Oscar Cordero Llana, Benjamin Christopher Houghton, Federica Rinaldi, Hannah Taylor, Rafael J. Yáñez‐Muñoz, James B. Uney, Liang‐Fong Wong, Maeve A. Caldwell · 2014 · Molecular Therapy
55. Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
    Faith L. Anderson, Katharine M. von Herrmann, Angeline S. Andrew, Yuliya I. Kuras, Alison L. Young, Clemens R. Scherzer, William F. Hickey, Stephen Lee, Matthew C. Havrda · 2021 · npj Parkinson s Disease
56. Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
    Peter Franz Riederer, Sabrina Strobel, Toshiharu Nagatsu, Hirohisa Watanabe, Xiqun Michael Chen, Peter Andreas Löschmann, Jeswinder Sian‐Hülsmann, Wolfgang H. Jost, Thomas H. Müller, Johannes Martinus Dijkstra et al. · 2025 · Journal of Neural Transmission
57. Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
    M. Catarina Silva, Stephen J. Haggarty · 2019 · Annals of the New York Academy of Sciences
58. The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson’s Disease
    Georgia Minakaki, Dimitri Krainc, Lena F. Burbulla · 2020 · Frontiers in Cell and Developmental Biology
59. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease
    Merja H. Voutilainen, Urmas Arumäe, Mikko Airavaara, Märt Saarma · 2015 · FEBS Letters
60. Animal models of Parkinson’s disease: a guide to selecting the optimal model for your research
    Joana Lama, Yazead Buhidma, Edward J. R. Fletcher, Susan Duty · 2021 · Neuronal Signaling
61. Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice
    Savannah M. Rocha, Collin M. Bantle, Tawfik Aboellail, Debotri Chatterjee, Richard Jay Smeyne, Ronald B. Tjalkens · 2022 · Neurobiology of Disease
62. Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease
    Ariadna Laguna, Nicoletta Schintu, André Nobre, Alexandra Alvarsson, Nikolaos Volakakis, Jesper Kjaer Jacobsen, Marta Gómez‐Galán, Elena Sopova, Eliza Joodmardi, Takashi Yoshitake et al. · 2015 · Nature Neuroscience
63. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
    Iván Carrera, Ramón Cacabelos · 2018 · Current Neuropharmacology
64. Selective autophagy as a therapeutic target for neurological diseases
    Weilin Xu, Umut Ocak, Liansheng Gao, Sheng Tu, Cameron Lenahan, Jianmin Zhang, Anwen Shao · 2020 · Cellular and Molecular Life Sciences
65. Update on CSF Biomarkers in Parkinson’s Disease
    Eun Hae Kwon, Sabrina Tennagels, Ralf Gold, Klaus Bernhard Gerwert, Léon Beyer, Lars Tönges · 2022 · Biomolecules
66. Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice
    Stefano Cataldi, Jordan Follett, Jesse D. Fox, Igor Tatarnikov, Chelsie Kadgien, Emil Karl Gustavsson, Jaskaran Khinda, Austen J. Milnerwood, Matthew James Farrer · 2018 · npj Parkinson s Disease
67. Free-Water Imaging in White and Gray Matter in Parkinson’s Disease
    Christina Andica, Koji Kamagata, Taku Hatano, Asami Saito, Wataru Uchida, Takashi Ogawa, Haruka Takeshige‐Amano, Andrew Zalesky, Akihiko Wada, Michimasa Suzuki et al. · 2019 · Cells
68. Microtissue Engineered Constructs with Living Axons for Targeted Nervous System Reconstruction
    D. Kacy Cullen, Min D. Tang‐Schomer, Laura A. Struzyna, Ankur Patel, Victoria E. Johnson, John A. Wolf, Douglas H. Smith · 2012 · Tissue Engineering Part A
69. Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson’s Disease
    Kyle Farmer, Catherine A. Smith, Shawn P. Hayley, Jeffrey C. Smith · 2015 · International Journal of Molecular Sciences
70. Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI
    Frédérique Depierreux, Éric Parmentier, Laurane Mackels, Katherine Baquero, Christian Degueldre, Evelyne Balteau, Éric Salmon, Christophe L. M. Phillips, Mohamed Ali Bahri, Pierre Maquet et al. · 2021 · npj Parkinson s Disease
71. Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy
    Andrii Domanskyi, Märt Saarma, Mikko Airavaara · 2015 · Human Gene Therapy
72. Tsc1-mTORC1 signaling controls striatal dopamine release and cognitive flexibility
    Polina Kosillo, Natalie M. Doig, Kamran M. Ahmed, Alexander H.C.W. Agopyan-Miu, Corinna D. Wong, Lisa Conyers, Sarah Threlfell, Peter J. Magill, Helen S. Bateup · 2019 · Nature Communications
73. Dopaminergic abnormalities following traumatic brain injury
    P. Jenkins, S. De Simoni, N. Bourke, Jessica Fleminger, Gregory P. T. Scott, D. Towey, W. Svensson, Sameer Khan, Maneesh C. Patel, R. Greenwood et al. · 2018 · Brain : a journal of neurology
74. Rebuilding Brain Circuitry with Living Micro-Tissue Engineered Neural Networks
    Laura A. Struzyna, John A. Wolf, Constance Jennifer Mietus, Dayo O. Adewole, Han-Chiao Isaac Chen, Douglas H. Smith, D. Kacy Cullen · 2015 · Tissue Engineering Part A
75. Relationship between neuromelanin and dopamine terminals within the Parkinson’s nigrostriatal system
    Antonio Martín‐Bastida, Nicholas P Lao–Kaim, Andreas–Antonios Roussakis, Graham E. Searle, Yue Xing, Roger N. Gunn, Stefan Theodor Schwarz, Roger A. Barker, Dorothee P. Auer, Paola P. Piccini · 2019 · Brain
76. Using Graphene-Based Biosensors to Detect Dopamine for Efficient Parkinson’s Disease Diagnostics
    Małgorzata Kujawska, Sheetal Kaushik Bhardwaj, Yogendra Kumar Mishra, Ajeet Kumar Kaushik · 2021 · Biosensors
77. Striatal synaptic adaptations in Parkinson's disease
    Weixing Shen, Shenyu Zhai, Dalton James Surmeier · 2022 · Neurobiology of Disease
78. A predictive model to identify Parkinson disease from administrative claims data
    Susan Searles Nielsen, Mark N. Warden, Alejandra Camacho‐Soto, Allison Wright Willis, Brenton A. Wright, Brad Alan Racette · 2017 · Neurology
79. Mimicking Human Pathophysiology in Organ‐on‐Chip Devices
    Özlem Yeşil-Çeliktaş, Shabir Hassan, Amir Kamal Miri, Sushila Maharjan, Rawan Al‐kharboosh, Alfredo Quiñones‐Hinojosa, Yu Shrike Zhang · 2018 · Advanced Biosystems
80. Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer’s Disease, Parkinson’s Disease, and Depression with Pharmacokinetic and Safety Profiles
    H. Do, Jungsook Cho · 2020 · International Journal of Molecular Sciences
81. Age- and α-Synuclein-Dependent Degeneration of Dopamine and Noradrenaline Neurons in the Annual Killifish Nothobranchius furzeri
    Hideaki Matsui, Naoya Kenmochi, Kazuhiko Namikawa · 2019 · Cell Reports
82. Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson’s Disease
    Ane Murueta‐Goyena, Ane Andikoetxea, Juan Carlos Gómez‐Esteban, Iñigo Gabilondo · 2019 · Frontiers in Pharmacology
83. Non-Motor Symptoms of Parkinson’s Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction
    Ayan Hussein, Christopher A. Guevara, Pamela Del Valle, Swati Gupta, Deanna L. Benson, George W. Huntley · 2021 · The Neuroscientist
84. The NRF2-Dependent Transcriptional Regulation of Antioxidant Defense Pathways: Relevance for Cell Type-Specific Vulnerability to Neurodegeneration and Therapeutic Intervention
    Stephanie M. Boas, Kathlene L. Joyce, Rita Marie Cowell · 2021 · Antioxidants
85. A Review of Non-Invasive Drug Delivery through Respiratory Routes
    Yongbo Zhang, Dong Wu Xu, Lu Bai, Yan-Ming Zhou, Han Zhang, Yuan‐Lu Cui · 2022 · Pharmaceutics
86. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues
    Elisa Menozzi, Marco Toffoli, Anthony H.V. Schapira · 2023 · Pharmacology & Therapeutics
87. Stem cell therapies in age-related neurodegenerative diseases and stroke
    Yuan Wang, Xunming Ji, Rehana K. Leak, Fenghua Chen, Guodong Cao · 2016 · Ageing Research Reviews
88. The Role of Lipids in the Initiation of α-Synuclein Misfolding
    Martin Kiechle, Veselin Grozdanov, Karin M. Danzer · 2020 · Frontiers in Cell and Developmental Biology
89. Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease
    Peter Franz Riederer, Camelia Monoranu, Sabrina Strobel, T. Iordache, Jeswinder Sian‐Hülsmann · 2021 · Journal of Neural Transmission
90. CircEPS15, as a sponge of MIR24-3p ameliorates neuronal damage in Parkinson disease through boosting PINK1-PRKN-mediated mitophagy
    Yuanzhang Zhou, Yang Liu, Zhengwei Kang, Hang Ping Yao, Nanshan Song, Min Wang, Chenghuan Song, Kezhong Zhang, Jianhua Ding, Juanjuan Tang et al. · 2023 · Autophagy
91. α-Synuclein in the olfactory system in Parkinson’s disease: role of neural connections on spreading pathology
    Isabel Úbeda‐Bañón, Daniel Saiz‐Sánchez, Carlos de la Rosa‐Prieto, Alino Martı́nez-Marcos · 2013 · Brain Structure and Function
92. The pathomechanisms underlying Parkinson's disease
    K. A. Jellinger · 2014 · Expert Review of Neurotherapeutics
93. New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota
    Lorente-Picón, Marina, Laguna, Ariadna · 2021 · Biomolecules
94. Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
    Peter Franz Riederer, Toshiharu Nagatsu, Moussa B. H. Youdim, Maximilian Wulf, Johannes Martinus Dijkstra, Jeswinder Sian‐Hülsmann · 2023 · Journal of Neural Transmission
95. Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment
    Lloyd A. Greene, Oren Levy, Cristina Malagelada · 2011 · Cellular and Molecular Neurobiology
96. Implications of Circadian Rhythm in Dopamine and Mood Regulation
    Jeong‐Ah Kim, Sang-Won Jang, Han Kyoung Choe, Sooyoung Chung, Gi Hoon Son, Kyungjin Kim · 2017 · Molecules and Cells
97. Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease
    Ruilai Jiang, Chunjiao Rong, Ronghu Ke, Shuiyan Meng, Xiumei Yan, Honglin Ke, Shaochang Wu · 2019 · Medicine
98. Development of stem cell-based therapy for Parkinson’s disease
    Fabin Han, Deborah Baremberg, Junyu Gao, Jing Duan, Xianjie Lu, Nan Zhang, Qingfa Chen · 2015 · Translational Neurodegeneration
99. Is criticality a unified setpoint of brain function?
    Keith B. Hengen, Woodrow L. Shew · 2025 · Neuron
100. Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease
     Veronica Francardo, Yvonne Schmitz, David L. Sulzer, Maria Angela Cenci · 2017 · Experimental Neurology